NCT05041842: Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer

NCT05041842
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Endocrine (Hormone Therapy, Tyrosine-Kinase Inhibitor, Therapeutic antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with leptomeningeal disease; Patients with previous treatment of a tyrosine kinase inhibitor (e.g. Tukysa/tucatinib, Nerlynx/neratinib, Tykerb/lapatinib)
https://ClinicalTrials.gov/show/NCT05041842

Comments are closed.

Up ↑